Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 500-003-1 | CAS number: 9003-13-8
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Short description of key information on bioaccumulation potential result:
No ADME studies are available for tripropylene glycol n-butyl ether-highers (TPnB-highers) as such. Therefore, the toxicokinetics assessment is based on the available data for structurally related propylene glycol ethers (PGEs) such as propylene glycol methyl ether (PM), dipropylene glycol methyl ether DPM, tripropylene glycol methyl ether (TPM), propylene glycol n-butyl ether (PnB) and dipropylene glycol n-butyl ether (DPnB).
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
Additional information
No ADME studies are available for tripropylene glycol n-butyl ether highers (TPnB-highers) as such. Therefore, the toxicokinetics assessment is based on the available data for structurally related propylene glycol ethers (PGEs) such as propylene glycol methyl ether (PM), dipropylene glycol methyl ether DPM, tripropylene glycol methyl ether (TPM), propylene glycol n-butyl ether (PnB) and dipropylene glycol n-butyl ether (DPnB). As a class, the propylene glycol ethers are rapidly absorbed and distributed throughout the body when introduced by inhalation or oral exposure. Metabolism studies (by oral exposure) conducted with several PGEs support this conclusion. While not tested directly, absorption by inhalation exposure also would be expected to be rapid for PGEs aerosols that are in the respirable range. However, due to the low vapor pressure of TPnB-highers no inhalation exposure is expected for this substance. Dermal absorption is expected to be somewhat slower but, once absorbed, subsequent distribution also should be rapid. When a single dose of DPnB was administered orally to rats, most of the dose was eliminated within 48 hours indicating rapid excretion. Similar rapid absorption, distribution, and elimination occurred within 48 hours for TPM. Most excretion for PGEs is via the urine and expired air. A small portion is excreted in the feces. In analogy to PnB and DPnB the metabolism of TPnB-highers is expected to take place predominantly in the liver where mixed function oxidase cleaves the ether linkage, yielding propylene glycol and an alcohol. These two products may be further metabolised to CO2 and water, with the latter ultimately being excreted in expired air. Alternatively, TPnB-highers (or intermediate metabolites) may be conjugated in the liver with glucuronide, sulfate, or glutathione for ultimate excretion, predominantly in the urine. TPnB-highers is expected to be rapidly absorbed and distributed throughout the body when introduced by oral exposure. Dermal absorption is expected to be somewhat slower but subsequent distribution will be rapid.
Discussion on bioaccumulation potential result:
As a class, the propylene glycol ethers are rapidly absorbed and distributed throughout the body when introduced by inhalation or oral exposure. Metabolism studies (by oral exposure) conducted with several PGEs support this conclusion. While not tested directly, absorption by inhalation exposure also would be expected to be rapid for aerosols of PGEs that are in the respirable range. However, due to the low vapor pressure of TPnB-highers no inhalation exposure is expected for this substance. Dermal absorption is expected to be somewhat slower but, once absorbed, subsequent distribution also should be rapid. When a single dose of DPnB was administered orally to rats, most of the dose was eliminated within 48 hours indicating rapid excretion. Similar rapid absorption, distribution, and elimination occurred within 48 hours for TPM. Most excretion for PGEs is via the urine and expired air. A small portion is excreted in the feces. In analogy to PnB and DPnB the metabolism of TPnB-highers is expected to take place predominantly in the liver where mixed function oxidase cleaves the ether linkage, yielding propylene glycol and an alcohol. These two products may be further metabolised to CO2 and water, with the latter ultimately being excreted in expired air. Alternatively, TPnB-highers (or intermediate metabolites) may be conjugated in the liver with glucuronide, sulfate, or glutathione for ultimate excretion, predominantly in the urine. TPnB-highers is expected to be rapidly absorbed and distributed throughout the body when introduced by oral exposure. Dermal absorption is expected to be somewhat slower but subsequent distribution will be rapid.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
